LifeScience Emerging Biotech
Nanyang Biologics to Go Public Through Business Combination with RF Acquisition Corp II Valued at 1.5 Billion USD
Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform ...
October 03, 2025 | News
WuXi XDC Co-Hosts 2025 BPD Singapore Summit Showcasing Innovation in Bioconjugates and Global Biopharma Collaboration
The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully conclude...
September 30, 2025 | News
Galux Validates AI-Driven Platform with Atomic-Level Precision in De Novo Antibody Design
Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody Finding...
September 23, 2025 | News
CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS
CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...
September 22, 2025 | News
EC Approves Alteogen’s EYLUXVI® as Eylea® Biosimilar for Major Ophthalmic Indications
EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through it...
September 18, 2025 | News
Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate
Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...
September 16, 2025 | News
Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer
Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...
September 16, 2025 | News
BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...
September 16, 2025 | News
Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer
Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...
September 15, 2025 | News
Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma
Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...
September 15, 2025 | News
YolTech Raises $45 Million in Series B Funding to Propel In Vivo Gene-Editing Therapies
YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $...
September 12, 2025 | News
Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...
September 12, 2025 | News
iRegene Secures Over RMB 300 Million in Landmark Series B+ Financing to Advance First-in-Class iPSC Cell Therapies
iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, ...
September 10, 2025 | News
Epigenic Therapeutics Raises $60 Million in Series B Financing to Advance Epigenetic Medicine Pipeline
Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series ...
September 09, 2025 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
